● Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Condition: B-cell Acute Lymphoblastic Leukemia (B-ALL) · Sponsor: AstraZeneca

PhasePhase 1/Phase 2

Planned participants236

Who can joinAll sexes, 12 Years to no upper limit

Healthy volunteersNo

About this study

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 prior lines of therapies. The study will consist of 3 parts. Part A monotherapy dose escalation. Part B dose optimisation. Part C Dose expansion at the recommended phase 2 dose (RP2D)

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (80)

Research Site	Birmingham, Alabama, United States	Withdrawn
Research Site	Duarte, California, United States	Recruiting
Research Site	Los Angeles, California, United States	Recruiting
Research Site	Palo Alto, California, United States	Recruiting
Research Site	Tampa, Florida, United States	Recruiting
Research Site	Atlanta, Georgia, United States	Recruiting
Research Site	Chicago, Illinois, United States	Recruiting
Research Site	New York, New York, United States	Recruiting
Research Site	Houston, Texas, United States	Recruiting
Research Site	Richmond, Virginia, United States	Recruiting
Research Site	Seattle, Washington, United States	Withdrawn
Research Site	Milwaukee, Wisconsin, United States	Recruiting

+ 68 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06137118